Tarsus Pharmaceuticals (TARS) Total Liabilities (2019 - 2026)

Tarsus Pharmaceuticals' Total Liabilities history runs 8 years deep, the most recent figure standing at $232.2 million for Q1 2026.

• In Q1 2026, Total Liabilities rose 46.68% year-over-year to $232.2 million; the TTM figure through Mar 2026 stood at $232.2 million (up 46.68% YoY), while the FY2025 annual figure was $218.7 million, up 43.47% from the prior year.
• Total Liabilities for Q1 2026 stood at $232.2 million, up from $218.7 million in the prior quarter.
• The five-year high for Total Liabilities was $232.2 million in Q1 2026, with the low at $31.3 million in Q2 2022.
• The 5-year median for Total Liabilities is $74.1 million (2024), against an average of $105.6 million.
• The sharpest annual moves came in 2023 and 2024: Total Liabilities gained 17.11% in 2023, then jumped 202.44% in 2024.
• Tarsus Pharmaceuticals' Total Liabilities stood at $35.0 million in 2022, then surged by 95.93% to $68.5 million in 2023, then jumped by 122.56% to $152.5 million in 2024, then surged by 43.47% to $218.7 million in 2025, then gained by 6.15% to $232.2 million in 2026.
• Business Quant data shows TARS's Total Liabilities at $232.2 million in Q1 2026, $218.7 million in Q4 2025, and $199.5 million in Q3 2025.